The objective of this study was to construct our recently developed aptamer-modified 24 targeted liposome nano-carrier (Apt-PEG-LPs) system to target primary cultured mouse 25 tumor endothelial cells (mTEC), both in vitro and in vivo. We first synthesized an aptamer-26 polyethylene glycol 2000-distearoyl phosphoethanolamine (Apt-PEG 2000 -DSPE). The 27 conjugation of the Apt-PEG 2000 -DSPE was confirmed by MALDI-TOF mass spectroscopy. A 28 lipid hydration method was used to prepare Apt-PEG-LPs, in which the the outer surface of 29 the PEG-spacer was decorated with the aptamer. Apt-PEG-LPs were significantly taken up 30 by mTECs. Cellular uptake capacity was observed both quantitatively and qualitatively using 31 spectrofluorometry, and confocal laser scanning microscopy (CLSM), respectively. In 32 examining the extent of localization of aptamer-modified liposomes that entered the cells, 33 approximately 39% of the Apt-PEG-LPs were not co-localized with lysotracker, indicating 34 that they had escaped from endosomes. The uptake route involved a receptor mediated 35 pathway, followed by clathrin mediated endocytosis. This Apt-PEG-LP was also applied for 36 in vivo research whether this system could target tumor endothelial cells. Apt-PEG-LP and 37 PEG 5000 -DSPE modified Apt-PEG-LP (Apt/PEG 5000 -LP) were investigated by human renal 38 cell carcinoma (OS-RC-2 cells) inoculating mice using CLSM. Apt-PEG-LP and 39
Introduction

54
A continuous affordable, but still greater challenge remains in nano-medicine in terms of 55 cancer diagnosis, and therapy designed to deliver imaging agents or chemotherapeutic drugs leakiness and have a basement membrane that is thick and uneven. This suggests that tumor 117 endothelial cells may well express surface markers that are different from those found in 118 normal cells [30, 31] . Our rationale for targeting tumor endothelial cells in our current project 119 is based on the following assumptions, Tumor endothelial cells can support many tumor cells, 120 and thus, targeting endothelial cells might be a much more effective strategy than targeting 121 actual tumor cells themselves. In fact, active targeting can be achieved by the efficient 122 recognition of specific antigens that are expressed on the cell surface proteins of tumor cells 123 but are not expressed on normal cells [32] [33] [34] [35] [36] . Therefore, the ligand attached on the surface of 124 PEGylated liposomes such as Apt-PEG-LPs can be enhanced the cellular uptake. 125 We recently isolated a DNA aptamer AraHH001 (Kd = 43 nM) that is selectively 126 expressed on the mates of different origin and does not bind to healthy endothelial cells. 127 Additionally, this aptamer has a high internalization capacity [37] , providing a means for the 128 intracellular delivery of drugs or gene therapy that are themselves not permeable to cells. For 129 this reason, we selected this high affinity aptamer for use in the current study. We established 130 a aptamer-based mTECs targeted liposomal drug delivery system which enhanced the uptake 131 into target mTECs compared to PEGylated liposomes, and conducted a detailed study of the 132 uptake mechanism and intracellular tarfficking for this system. To perform a quantitative cellular uptake analysis, 4 × 10 4 cells were seeded per cm 2 in 187 24-well plates (Corning Incorporated, Corning, NY, USA) and incubated overnight at 37 °C 188 in an atmosphere of 5% CO 2, and in 95% humidity. On the next experimental day, medium 189 from cells in 24 well-plates was removed by aspiration and the cells then washed with warm 190 PBS once. A different rhodamine labeled liposomal solution was then added to the cells, 191 followed by incubation for 3 h at 37 °C in an atmosphere of 5% CO 2, and in 95% humidity.
192
After 3 h of incubation, the cells were washed with 1× warm PBS supplemented with 100 nM were examined by confocal laser scanning microscopy, as described above.
234 235 2.9. Investigation of the cellular uptake mechanism using excess unlabeled Apt-PEG-LPs by 236 Confocal Laser scanning Microscope (CLSM) 237 For the investigation of uptake mechanism, mTECs were prepared as described above.
238
The cells were incubated with labeled and labeled-unlabeled (1:2 ratio) Apt-PEG-LPs (5 239 mole% of the total lipid) in Kreb's buffer for 3 h at 37 °C under an atmosphere with 5% CO 2 240 and in 95% humidity. Apt-PEG-LPs were labeled with 1 μL Rhodamine (1 mM). After 2.5 h 241 of incubation, 20 μl of Hoechst 33342 (1 mg/mL) was added to stain the nuclei and the 242 suspension was re-incubated for an additional 30 min. After two to three washings, the cells For the qualitative CLSM studies to investigate the mechanism of internalization of the 249 modified Apt-PEG-LPs, 2 × 10 5 cells were seeded in a 35 mm glass bottom dish in 2 mL medium and then incubated overnight at 37 °C in an atmosphere of 5% CO2 and 95% 251 humidity. The cells were washed with 1 mL of 1× PBS and then pre-incubated with Kreb's 252 buffer for various times in the absence or presence of the following inhibitors: Amiloride (1 253 mM) for 10 min; Sucrose (0.25 M) for 30 min or Filipin III (1 μg/mL) for 30 min at 37 °C.
254
The various inhibitors were removed by aspiration, followed by washing once with Krebs 255 buffer and the Apt-PEG-LPs were added to the cells, followed by incubation for 1 h at 37 °C.
256
The cells were washed twice by adding 1 mL of PBS supplemented with 100 nM cholic acid.
257
Finally the cells in 1 mL Krebs buffer were observed under the Confocal Laser scanning 258 Microscope.
259
To quantitatively investigate the mechanism of internalization of the modified Apt-PEG-
260
LPs, 4 × 10 4 cells were seeded in a 24-well plate (Corning incorporated, Corning, NY, USA) 261 and the plate was incubated overnight at 37 °C in an atmosphere of 5% CO2 and 95% 262 humidity. The cells were washed with 1 mL of PBS and then pre-incubated with Kreb's 263 buffer for various times in the absence or presence of the following inhibitors: Amiloride (1 264 mM) for 10 min; Sucrose (0.25 M) for 30 min or Filipin III (1 μg/mL) for 30 min at 37 °C.
265
The various inhibitors were removed by aspiration, followed by washing once with Krebs 266 buffer and then Apt-PEG-LPs were added in the cells to incubate for 1 h at 37 °C. The cells LPs was found to be almost 3.8 fold higher than that for PEG-LPs used as the control (Fig.   313 2). The enhanced cellular uptake in terms of relative fluorescence intensity was statistically 314 significant compared to control PEG-LPs. The cellular uptake of Apt-PEG-LPs and PEG LPs by mTECs was also tested by CLSM, 319 as shown in (Fig. 3) . The cellular uptake of PEG-LP was used as a negative control, showing 320 a very weak fluorescence signal, representing that the only small amount of PEG-LPs were 321 internalized into the cells. Compared to the control, our aptamer AraHH001 modified 322 PEGylated liposomal nano-carrier system resulted in a higher uptake capacity, and at the same time, showed an enhanced ability to recognize the target protein on cell surface indicating that they were located in the lysosomal compartment (Fig. 4A ). The remaining 333 portions about 39% appeared as a non-colocalized form into the cells (Fig. 4B ). Image Pro To confirm the pathway responsible for the receptor mediated uptake of the Apt-PEG-LPs, 340 we carried out acompetition uptake assay with Rhodamine labeled and unlabeled (1:2) Apt-341 PEG-LPs in mTECs. Only Rhodamine labeled Apt-PEG-LPs was used in this uptake assay as 342 a control (Fig. 5 ). The competition assay was successful in blocking the target receptor to a 343 certain extent so that uptake inhibition was apparent compared to the control labeled Apt-344 PEG-LPs. caveolae-mediated inhibitors [38] were used to determine the uptake rate for Apt-PEG-LPs.
352
An in vitro CLSM uptake study in the presence of different inhibitors showed that the 353 targeted Apt-PEG-LPs were inhibited significantly by clathrin mediated pathways, 354 irrespective of whether other inhibitors had any influence on the uptake process ( Fig. 6A ). To 355 further verify this conclusion, a quantitative analysis of uptake inhibition using different 356 inhibitors was performed, as described above. The results indicated that the entry route 357 followed by Apt-PEG-LPs was the same and the uptake was largely inhibited by sucrose ( Fig.   358 6B). was incorporated, almost all of the LPs were observed in tumor vessels ( Fig. 7) . On the other hand, LPs modified with 1 or 2.5 mole% Apt-PEG 2000 -DSPE were spread within the tumor 374 xenograft. As to normal organs, the Apt-PEG-LPs were highly accumulated in the liver and 375 spleen, but not in the heart, in which the target protein of AraHH001, troponin T, is expressed 376 (Fig. S1 ).
377
To evaluate the selectivity of the shown in (Fig. S2) . In fact, the PEG-LPs were found to bare binded to TECs (3%), wheras 385 the aptamer modified LPs were highly co-localized with the TECs (Apt-PEG-LPs 16%,
386
Apt/PEG 5000 -LPs 25%) ( Fig. 8) . 
